References
- Creamer MR, Wang TW, Babb S, Cullen KA, Day H, Willis G, Jamal A, Neff L. Tobacco product use and cessation indicators among adults – united states, 2018. Morbidity and Mortality Weekly Report 2019, 68(45);1013-1019.
- Parker MA, Streck JM, Sigmon SC. Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. Drug Alcohol Depend. 2018;186:167–70. doi:https://doi.org/10.1016/j.drugalcdep.2018.01.024.
- Rajabi A, Dehghani M, Shojaei A, Farjam M, Motevalian SA. Association between tobacco smoking and opioid use: A meta-analysis. Addict Behav. 2019;92:225–35. doi:https://doi.org/10.1016/j.addbeh.2018.11.043.
- Pajusco B, Chiamulera C, Quaglio G, Moro L, Casari R, Amen G, Faccini M, Lugoboni F. Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy. Int J Environ Res Public Health. 2012;9:932–42.
- Guydish J, Passalacqua E, Pagano A, Martinez C, Le T, Chun J, Tajima B, Docto L, Garina D, Delucchi K. An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111:220–30.
- Harrell PT, Trenz RC, Scherer M, Pacek LR, Latimer WW. Cigarette smoking, illicit drug use, and routes of administration among heroin and cocaine users. Addict Behav. 2012;37:678–81. doi:https://doi.org/10.1016/j.addbeh.2012.01.011.
- McHugh RK, Votaw VR, Fulciniti F, Connery HS, Griffin ML, Monti PM, Weiss RD. Perceived barriers to smoking cessation among adults with substance use disorders. J Subst Abuse Treat. 2017;74:48–53.
- Talka R, Tuominen RK, Salminen O. Methadone’s effect on nAChRs–a link between methadone use and smoking? Biochem Pharmacol. 2015;97:542–49. doi:https://doi.org/10.1016/j.bcp.2015.07.031.
- Chait LD, Griffiths RR. Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther. 1984;229:636–40.
- Schmitz JM, Grabowski J, Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 1994;34:237–42. doi:https://doi.org/10.1016/0376-8716(94)90162-7.
- Richter KP, Hamilton AK, Hall S, Catley D, Cox LS, Grobe J. Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007;15:144–53. doi:https://doi.org/10.1037/1064-1297.15.2.144.
- Frosch DL, Shoptaw S, Nahom D, Jarvik ME. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Exp Clin Psychopharmacol. 2000;8:97–103. doi:https://doi.org/10.1037/1064-1297.8.1.97.
- Gorelick DA, Rose J, Jarvik ME. Effect of naloxone on cigarette smoking. J Subst Abuse. 1988;1:153–59. doi:https://doi.org/10.1016/S0899-3289(88)80018-X.
- Talka R, Salminen O, Tuominen RK. Methadone is a non-competitive antagonist at the alpha4beta2 and alpha3* nicotinic acetylcholine receptors and an agonist at the alpha7 nicotinic acetylcholine receptor. Basic Clin Pharmacol Toxicol. 2015;116:321–28. doi:https://doi.org/10.1111/bcpt.12317.
- Berrendero F, Robledo P, Trigo JM, Martin-Garcia E, Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev. 2010;35:220–31. doi:https://doi.org/10.1016/j.neubiorev.2010.02.006.
- Wang AL, Elman I, Lowen SB, Blady SJ, Lynch KG, Hyatt JM, O’Brien CP, Langleben DD. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. Transl Psychiatry. 2015;5:e531.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33; quiz4-57.
- McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213.
- Sobell L, Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, editors. Measuring Alcohol Consumption. Clifton: Human Press; 1992. p. 41–72.
- Hurt RD, Offord KP, Croghan IT, Gomez-Dahl L, Kottke TE, Morse RM, Melton LJ, 3rd. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996;275:1097–103.
- Tsoh JY, Chi FW, Mertens JR, Weisner CM. Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes. Drug Alcohol Depend. 2011;114:110–18. doi:https://doi.org/10.1016/j.drugalcdep.2010.09.008.
- Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl). 1998;140:185–90. doi:https://doi.org/10.1007/s002130050756.
- Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004;77:29–37. doi:https://doi.org/10.1016/j.pbb.2003.09.017.
- King A, Cao D, Zhang L, Rueger SY. Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction. 2013;108:1836–44. doi:https://doi.org/10.1111/add.2013.108.issue-10.
- Lee YS, Joe KH, Sohn IK, Na C, Kee BS, Chae SL. Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:639–47. doi:https://doi.org/10.1016/j.pnpbp.2005.04.008.
- King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000;66:563–72. doi:https://doi.org/10.1016/S0091-3057(00)00258-6.
- O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166:667–74.
- Mannelli P, Wu LT, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res. 2013. doi:https://doi.org/10.1093/ntr/ntt046.
- David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2013 Jun 6;6:CD003086.
- Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18:31–40. doi:https://doi.org/10.1300/J069v18n01_04.
- King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8:671–82. doi:https://doi.org/10.1080/14622200600789767.
- King AC, Cao D, O’Malley SS, Kranzler HR, Cai X, deWit H, Matthews AK, Stachoviak RJ. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630–36.
- Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED, Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse. 2015;41:35–44. doi:https://doi.org/10.3109/00952990.2014.927881.
- Roche DJ, King AC. Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. Psychoneuroendocrinology. 2015;52:59–71. doi:https://doi.org/10.1016/j.psyneuen.2014.10.013.
- Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32:503–17. doi:https://doi.org/10.1080/00952990600918973.
- Kohut SJ. Interactions between nicotine and drugs of abuse: a review of preclinical findings. Am J Drug Alcohol Abuse. 2017;43:155–70. doi:https://doi.org/10.1080/00952990.2016.1209513.
- Norman H, D’Souza MS. Endogenous opioid system: a promising target for future smoking cessation medications. Psychopharmacology (Berl). 2017;234:1371–94. doi:https://doi.org/10.1007/s00213-017-4582-0.
- Maselli DJ, Bhatt SP, Anzueto A, Bowler RP, DeMeo DL, Diaz AA, Dransfield MT, Fawzy A, Foreman MG. Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. Chest. 2019;156:228–38.
- Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking-attributable morbidity in the United States. JAMA Intern Med. 2014;174:1922–28. doi:https://doi.org/10.1001/jamainternmed.2014.5219.
- Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest. 2000;117:354S–9S. doi:https://doi.org/10.1378/chest.117.5_suppl_2.354S.
- Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1–32. doi:https://doi.org/10.1146/annurev.clinpsy.3.022806.091415.